- Home
- LPAA vs SLN Comparison
LPAA vs SLN Comparison
Compare LPAA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | SLN |
|---|---|---|
| Founded | 2024 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.3M | 318.4M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | LPAA | SLN |
|---|---|---|
| Price | $10.64 | $4.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 29.9K | ★ 283.0K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | ★ $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.91 | ★ N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $10.09 | $1.97 |
| 52 Week High | $10.73 | $7.78 |
Technical Indicators
Market Signals| Indicator | LPAA | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 35.35 |
| Support Level | $10.63 | $4.22 |
| Resistance Level | $10.70 | $4.97 |
| Average True Range (ATR) | 0.01 | 0.44 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 25.00 | 18.85 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.